MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.urolonc.2026.04.297

Медицинская библиотека · Urologic oncology · 2026

Adverse pathology and low tumor volume in biopsy Gleason 3 + 4 prostate cancer: Toward safe expansion of active surveillance and focal therapy.

Ozawa Yu, Moschovas Marcio Covas, Sandri Marco, Sharma Rohan, Saikali Shady, Diamond Ari, Rogers Travis, Patel Vipul

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

The criteria for active surveillance and focal therapy in Gleason score (GS) 3 + 4 disease remain unclear. We aimed to refine them by evaluating predictors of adverse pathology and low-volume disease at radical prostatectomy (RP).

METHODS

We retrospectively analyzed 1,665 men with biopsy GS 3 + 4 disease who underwent RP. Associations of biochemical recurrence (>0.2 ng/ml) and three definitions of adverse pathology were evaluated using Cox models: (1) GS ≥4 + 3 or pT3a-4, (2) GS ≥4 + 3 or pT3b-4, and (3) GS ≥4 + 4 or pT3a-4. The definition with the highest C-index was selected as the primary endpoint. Preoperative clinicopathological and MRI predictors of the selected adverse pathology were identified using multivariable logistic regression. With the same predictors, tumor diameter and volume at RP were assessed. The low-risk criteria were defined as a ≤ 20% predicted risk of the selected adverse pathology.

RESULTS

Definition 2 yielded the highest C-index (0.76; 95% CI, 0.71-0.81). Independent predictors were age, Black race, PSA, cT stage, maximum involvement of biopsy core (%), and MRI-detected extracapsular extension or seminal vesicle invasion. They were consistently associated with larger tumor diameter and volume, except for age and race. The low-risk criteria were defined as PSA ≤5 ng/ml, cT1 stage, absence of extracapsular extension or seminal vesicle invasion, and cancer involvement ≤30% of any core. The limitation was surgical selection bias.

CONCLUSIONS

Four preoperative predictors, supported by pathologically confirmed low-volume disease, provide a practical framework to refine selection for active surveillance and focal therapy in GS 3 + 4 disease. External prospective validation is warranted.

Для цитирования: Ozawa Yu, Moschovas Marcio Covas, Sandri Marco, Sharma Rohan, Saikali Shady, Diamond Ari, Rogers Travis, Patel Vipul. Adverse pathology and low tumor volume in biopsy Gleason 3 + 4 prostate cancer: Toward safe expansion of active surveillance and focal therapy.. Urologic oncology. 2026. DOI: 10.1016/j.urolonc.2026.04.297.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.